J
Jochen Schmitz
Researcher at Schering-Plough
Publications - 10
Citations - 3855
Jochen Schmitz is an academic researcher from Schering-Plough. The author has contributed to research in topics: Interleukin-21 receptor & Cytokine. The author has an hindex of 5, co-authored 9 publications receiving 3514 citations.
Papers
More filters
Journal ArticleDOI
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
Jochen Schmitz,Alexander Owyang,Elizabeth R. Oldham,Yaoli Song,Erin Murphy,Terril K. McClanahan,Gerard Zurawski,Mehrdad M. Moshrefi,Jinzhong Qin,Xiaoxia Li,Daniel M. Gorman,J. Fernando Bazan,Robert A. Kastelein +12 more
TL;DR: A member of theIL-1 family, IL-33, which mediates its biological effects via IL-1 receptor ST 2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T( H)2 cells is reported.
Journal ArticleDOI
IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor Complex
Alissa A. Chackerian,Elizabeth R. Oldham,Erin Murphy,Jochen Schmitz,Stefan Pflanz,Robert A. Kastelein +5 more
TL;DR: It is demonstrated that IL-33 and ST2 form a complex with IL-1R accessory protein (IL-1RAcP), a signaling receptor subunit that is also a member of the IL- 1R complex.
Patent
Use for interleukin-33 (il-33) and the il-33 receptor complex
TL;DR: In this paper, methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer, were provided. And methods of administering agonists or antagonists of IL-33 and IL-13 receptor.
Patent
Methods of modulating a mammalian cytokine
TL;DR: In this paper, methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer, were provided. And methods of administering agonists or antagonists of IL-33 and IL-13 receptor.
Patent
Use of agonists and antagonists of interleukin-33 (il-33)
TL;DR: In this paper, methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer, were provided. And methods of administering agonists or antagonists of IL-33 and IL-13 receptor.